7 results about "Nose running" patented technology

Tree pollen allergy is seasonal allergy caused by various tree pollen spread in air. The allergy affects a substantial proportion of populations, is particularly significant in European and North America areas, and is characterized by symptoms such as sneezing, nasal obstruction, rhinorrhea, eye itching and lacrimation, and throat irritation. The symptoms typically occur in spring, at which birch, alder, hazel and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by an immunoglobulin E (IgE) antibody. The present invention relates to antibodies and antigen binding fragments thereof that bind to one or more of tree pollen allergens Bet v 1, Aln g 1, Cor a 1 and Quue a 1, resulting in inhibition of IgE-mediated anaphylaxis.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

Tree pollen allergy is a seasonal allergy caused by various tree pollens suspended in the air. This allergy affects a significant proportion of the population, particularly in Europe and North America, and is characterized by symptoms such as sneezing, nasal congestion, runny nose, itchy or watery eyes, and throat inflammation. These symptoms typically occur in spring when trees such as birch, alder, hazel, and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by immunoglobulin E (IgE) antibodies. This invention relates to antibodies and their antigen-binding fragments that bind to one or more tree pollen allergens, Bet v 1, Aln g 1, Cor a 1, and Que a 1, and inhibit the IgE-mediated allergic reaction.

The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.

The utility model relates to the technical field of masks, and discloses an anti-fog mask which comprises a mask body, and a multifunctional anti-fog assembly is installed on the mask body. The multifunctional anti-fog assembly comprises a nose bridge fixing clamping piece, a pair of fixing ear ropes, a pair of anti-tightening cotton swabs, a fixing hook-and-loop fastener, a pair of moisture absorption cotton pieces, a pair of air blocking pieces, an air leakage prevention turnover piece and an absorption cleaning assembly. The utility model solves the problems that the conventional mask design only focuses on the basic protection function, such as filtering particulate matters in the air, but for a user wearing glasses, when the environment temperature is lower, fog generated by breathing can be exhaled from a gap at the upper edge and is easy to condense on lenses to influence the sight line; moreover, long-time wearing of the mask may cause discomfort of ears or pressing pain of the nose bridge, and the mask cannot be adjusted according to the size of the face of a user; when the mask is used, snot easily flows due to low temperature or illness, and the snot easily adheres to the mask, so that the recycling of the mask is influenced, and the use cost is increased.

The invention discloses a bispecific antibody fusion protein targeting double antigens and application of the bispecific antibody fusion protein. Relates to the technical field of biology. The bispecific antibody fusion protein constructed by the invention can be specifically combined with human IL-5 protein and human IgE protein. Animal experiments show that the fusion protein can significantly reduce the level of key inflammatory factors in an allergic rhinitis model mouse body, effectively relieve nasal symptoms such as sneezing and rhinorrhea, and show a good treatment effect. A novel candidate protein drug is provided for targeted therapy of allergic diseases, especially allergic rhinitis, and the protein has wide development and application prospects and important social value.

The invention discloses application of pummelo peel volatile oil in preparation of a medicine for preventing and treating allergic rhinitis. The pummelo peel volatile oil provided by the invention can be used for remarkably reducing the levels of mast cell factors IL-1beta and TNF-alpha, also can be used for remarkably reducing the levels of inflammatory factors IL-13 and IL-4 in a mouse body, and can be used for reducing inflammatory cell infiltration and reducing eosinophilic granulocytosis and gland hyperplasia. The pummelo peel volatile oil provided by the invention is used as a medicinal and edible raw material for treating allergic rhinitis, and has huge potential. The pummelo peel volatile oil provided by the invention can be used for remarkably improving symptoms such as sneezing, rhinorrhea and nose pruritus of mice caused by allergic rhinitis, and the symptoms seriously influence the life of patients.